Italia markets closed

Amicus Therapeutics, Inc. (0HF9.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
10,23-0,00 (-0,01%)
Alla chiusura: 02:53PM BST
Schermo intero
Chiusura precedente10,23
Aperto10,24
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno10,23 - 10,24
Intervallo di 52 settimane10,23 - 10,24
Volume705
Media VolumeN/D
Capitalizzazione29,989M
Beta (5 anni mensile)0,90
Rapporto PE (ttm)N/D
EPS (ttm)-0,97
Prossima data utili07 nov 2022 - 11 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Amicus Therapeutics Announces Participation at the 2022 AANEM Annual Meeting

    PHILADELPHIA, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced three poster presentations highlighting its development program for Pompe disease will be included at the 2022 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting, being held September 21-24, 2022 in Nashville, TN and virtually. Poster Presentations: Abstract Title: Long-term follow-up of cipaglucosidase alfa/miglustat in ambulatory patients with Pompe diseas

  • GlobeNewswire

    Amicus Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

    PHILADELPHIA, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference in New York, NY on Wednesday, September 14, 2022 at 12:20 p.m. E.T. A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations. About Amicus Therapeutics Amicu

  • GlobeNewswire

    Amicus Therapeutics Announces Second Quarter 2022 Financial Results

    1H22 Galafold® Revenue of $159.4M, reflecting 11% Sales Growth with Operational Growth of 18%, Partly Offset by Currency Headwinds of 7% On-Track to Deliver Full-Year Double-Digit Revenue Growth of 15-20% at Constant Exchange Rates Advancing U.S. and EU Regulatory Reviews and Launch Preparations for AT-GAA in Pompe Disease 3 Newly Issued U.S. Composition of Matter Patents for Galafold Add to Growing U.S. Patent Portfolio Conference Call and Webcast Today at 8:30 a.m. ET PHILADELPHIA, Aug. 04, 20